AURAAura Biosciences, Inc.
$6.50+13% 1Y
$6.50
$4.9752 weeks$8.90
AURA as reported
- Net income
- −$131M
Net income · +29% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$103M
Free cash flow · +23% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.75
EPS · −11% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$131M | +29% | Q2 2026 |
| EPS | −$1.75 | −11% | Q2 2026 |
| ROE | −73% | n/a | Q2 2026 |
| ROA | −59% | n/a | Q2 2026 |
| Free cash flow | −$103M | +23% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Aura Biosciences, Inc. (AURA) · Net incomeNet incomeAura Biosciences, Inc. (AURA)